🇬🇧 UK Manufactured & TestedCertificate of Analysis IncludedFor Research Use Only
Mercia Research
Tesamorelin — Mercia Research peptide

Lot 24-7010

Tesamorelin · 20mg

≥99.0%

Research applications

  • Visceral adipose modulation
  • Lipodystrophy models
  • IGF-1 axis research
For laboratory research use only. Not intended for human or animal consumption. Mercia Research supplies these compounds for in vitro research and analytical work by qualified personnel.

Sequence

C₂₂₁H₃₆₆N₇₂O₆₇S

Molecular weight

5135.79 g/mol

Purity

≥99.0%

Abbreviation

TESA

Storage

Lyophilized: −20 °C. Reconstituted: 2–8 °C, 7 days.

Reconstitution

Add 2 mL BAC water to a 10 mg vial → 5 mg/mL.

⚠ For laboratory research use only — not for human or animal consumption

Tesamorelin

Stabilised GHRH(1-44) analogue.

4.7 (162)

A GHRH(1-44) analogue with an N-terminal hexenoyl modification that confers resistance to DPP-IV cleavage. Studied in visceral-adiposity and IGF-1 axis models.

Configure

£100.00

Vial size

Lot 24-7010 · lot-matched COA included · cold-chain shipping

Qty

1
View Compare (0)

Research Overview

Tesamorelin is a synthetic analogue of human growth-hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid sequence with a trans-3-hexenoic acid group attached to the N-terminus. This modification confers resistance to DPP-IV enzymatic cleavage, extending its biological activity compared to native GHRH.

DPP-IV Resistance and Stability

The defining characteristic of Tesamorelin in research contexts is its enhanced stability. Studies have examined how the N-terminal hexenoyl modification protects against DPP-IV cleavage, the resulting extended half-life compared to unmodified GHRH analogues, and the implications for sustained GHRH receptor engagement in preclinical models.

Visceral Adipose Tissue Research

Tesamorelin has been studied in the context of visceral adiposity, particularly in relation to GH-mediated lipolysis in visceral adipose depots, IGF-1 axis stimulation and downstream metabolic effects, and lipodystrophy models where GH axis dysregulation affects fat distribution.

IGF-1 Axis Research

As a GHRH analogue, Tesamorelin stimulates endogenous GH secretion with downstream effects on IGF-1 production. Research has focused on hepatic IGF-1 synthesis in response to pulsatile GH stimulation, the IGF-1 binding protein profile under Tesamorelin-mediated GH pulses, and long-term axis dynamics in preclinical models.

For laboratory research use only. Not intended for human or animal consumption.